Financings In Brief: Alfacell
Executive Summary
Alfacell: Completes private placement of approximately $6 mil. The placement included the issuance of 1.6 mil. shares of common stock and 325,000 three-year warrants convertible to one share of common stock each at an exercise price of $7.50 per share. With the placement, Bloomfield, N.J.-based Alfacell will have approximately 13.5 mil. shares outstanding and operating funds for two years. Alfacell's lead product is the ribonuclease protein Onconase, which is in Phase III trials for advanced pancreatic cancer and a Phase II trial for malignant mesothelioma...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth